Contrarian Corpus
short seller

Citron Research

18 documents across the library, active from 2015 to 2026.

18 Documents
3.7 Avg. narrative
2.2 Avg. visual

Activity by year

15 1
17 1
18 4
19 3
20 2
23 2
24 3
25 1
26 1

All documents

Citron Research 2026-03-01

Credit Acceptance Corporation CACC

Citron reverses course on CACC: with CFPB/NYAG overhang resolved Feb 13 2026, 61% of float retired, and an Amazon-bred CEO, fair value is $714 (16x 2026E EPS of $44.62).

N4 V3 C3
Citron Research 2025-04-01

Vishay Precision Group VPG

VPG is the unnoticed picks-and-shovels supplier of precision sensors to Tesla's Optimus humanoid program; at $300M market cap and 0.9x book, Wall Street has completely missed the asymmetric upside.

N3 V2 C1
Citron Research 2024-12-01

Nebius Group NBIS

Nebius — the de-Russified Yandex remnant now an AI cloud pure-play backed by Nvidia and Accel — is mis-priced ahead of analyst coverage; Citron sees $50+.

N3 V2 C1
Citron Research 2024-09-24

Multiple (portfolio update)

AGL short worked: $5 PT set when stock was $25, fell to target on unprofitable model

N2 V2 C1
Citron Research 2024-04-11

Edgio, Inc. EGIO

Edgio trades at 0.13x sales despite serving Microsoft, Amazon, and Verizon; a takeout or rerating to peer CDN multiples implies $65-$200 per share — 6-10x upside.

N3 V2 C2
Citron Research 2023-11-06

Apellis Pharmaceuticals APLS

Citron shorts Apellis, arguing its new Geographic Atrophy drug Syfovre faces an imminent FDA warning as AAO ophthalmologists reject it 83%-17% and vasculitis cases mount.

N4 V2 C2
Citron Research 2023-04-19

Freedom Holding Corp FRHC

FRHC funnels 85% of revenue through a CEO-owned Belize affiliate (FFIN) sourcing Russian flows — an FTX/Alameda structure that should trigger restatement, sanctions violations, and Nasdaq delisting.

N4 V2 C1
Citron Research 2020-11-13

NIO Inc. NIO

NIO trades at 17-18x NTM EV/Sales — double Tesla's multiple — as a Made-in-China Model Y near $41K threatens the ES6/EC6; Citron closes its 2018 long at a $25 price target.

N3 V2 C1
Citron Research 2020-04-14

GSX Techedu GSX

Citron argues GSX Techedu is a near-total fraud — the vast majority of claimed K-12 students are bots, revenues are fabricated, and the stock is a zero.

N4 V2 C2
Citron Research 2019-12-10

Peloton Interactive PTON

Peloton trades at 2,286% above peers on EV per subscriber; once a cannibalizing app, undifferentiated hardware, and a March lockup wave hit, the stock collapses to $5.

N4 V2 C2
Citron Research 2019-06-01

FleetCor Technologies FLT

FleetCor's Clean Advantage carbon-offset program is a $100M+ green fraud — 97% of fees stay with FLT, demanding CEO Clarke's resignation and implying ~57% downside.

N4 V3 C3
Citron Research 2019-02-15

Inogen INGN

Inogen's growth is built on a reseller network that lies to elderly customers about Medicare coverage to force cash sales — competition and oversight will collapse margins to a $46 stock.

N4 V2 C2
Citron Research 2018-10-23

Tesla, Inc. TSLA

After five years short, Citron reverses on Tesla: Model 3 is dominating luxury and EV segments, Munro confirms 30% margins, and worst-case math yields $599/share.

N4 V2 C2
Citron Research 2018-08-28

Wayfair W

Wayfair's unit economics are deteriorating — loss per new customer nearly doubled to $19 — while the stock defies gravity; Citron is re-shorting with a first stop at $100.

N3 V2 C2
Citron Research 2018-08-21

NVIDIA Corporation NVDA

NVDA, up 600% since 2016, faces in-house silicon from every mega-customer, collapsing crypto and autonomous narratives, and a benchmark-less Turing launch — shares revert to $200.

N4 V2 C2
Citron Research 2018-05-31

Snap Inc. SNAP

SNAP trades at largest-ever discount to FB/TWTR despite fastest revenue growth

N4 V3 C2
Citron Research 2017-06-01

BlackBerry BBRY

QNX is entrenched in 60M cars across 40+ automakers — a leading autonomous-driving OS

N4 V2 C2
Citron Research 2015-10-21

Valeant Pharmaceuticals VRX

Philidor and R&O Pharmacy are the same entity — evidence of phantom accounts to book revenue

N5 V3 C3